Grifols, S.A. (NASDAQ:GRFS) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund grew its holdings in Grifols, S.A. (NASDAQ:GRFS) by 38.5% in the 4th quarter, Holdings Channel reports. The institutional investor owned 2,058,286 shares of the biotechnology company’s stock after buying an additional 572,439 shares during the quarter. New York State Common Retirement Fund’s holdings in Grifols were worth $23,794,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of GRFS. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Grifols by 106.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,132 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 1,618 shares during the period. Jump Financial LLC acquired a new stake in shares of Grifols in the 3rd quarter valued at approximately $136,000. Syon Capital LLC acquired a new stake in shares of Grifols in the 3rd quarter valued at approximately $250,000. Raymond James & Associates acquired a new stake in shares of Grifols in the 3rd quarter valued at approximately $254,000. Finally, NBC Securities Inc. acquired a new stake in shares of Grifols in the 3rd quarter valued at approximately $259,000.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft cut Grifols from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th.

Grifols Stock Up 1.8 %

Shares of GRFS stock opened at $6.38 on Friday. The stock has a fifty day moving average price of $6.92 and a 200 day moving average price of $8.32. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The company has a quick ratio of 1.32, a current ratio of 2.83 and a debt-to-equity ratio of 1.24.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.